“April 2017 : Intensification of the Company’s international development with the appointment of a new CEO : Mrs Nawal Ouzren”
“Sensorion aims to become a major player in the development of inner ear disease treatments of and thus fulfill unmet medical needs”
"Our mission is to develop innovative and targeted treatments for inner ear diseases with vertigo, tinnitus, hearing loss"
" Sensorion, has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential"

Vestibular Neuritis

Vestibular neuritis accounts for approximately 7% of patients who consult with vertigo 1. It has a male/female ratio of 1/1 and the most common age of onset is between 30 and 60 years old, with a peak at between 40 and 50 years old.  It has an annual incidence of between 1.7 (United Kingdom) and 3.5 (Japan) cases/100,000 people 2.  The underlying causes may be viral infection or a vascular origin in patients with a history of hypertension.


The symptoms are a combination of severe rotatory vertigo, nausea and vomiting but without tinnitus or hearing loss. The severity of symptoms is extremely incapacitating and patients often need to stay in bed (for up to 2 days).  This is a reason for visiting the emergency room.

The severity of symptoms, the generated disabilities and long-term complications of the disease process emphasize the need for specific treatments.


Current treatment involves two stages:

  •  Relieving the attack by isolating the patient and giving drugs to treat the vertigo, antiemetics for the nausea and even sedatives (benzodiazepines).  High, rapidly attenuated doses of systemic corticosteroids may be effective.  Antiviral agents however have not been shown to be effective. 3
  •  Vestibular rehabilitation with specialist rehabilitation practitioners to facilitate central vestibular compensation and therefore return to normal postural stabilisation and oculomotor reflexes.

[1] Strupp M, Zingler VC, Arbusow V, Niklas D, Maag KP, Dieterich M. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med. Jul 22 2004;351(4):354-61).
[2] Sekitani T, Imate Y, Noguchi T, et al. Vestibular neuronitis : Epidemiological survey by questionnaire in Japan. Acta Otolaryngol Suppl 1993;503:9-12.
[3] Hammani I. Prévalence de la migraine vestibulaire dans une consultation dédiée aux vertiges. Étude rétrospective sur 2012. Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale Volume 131, Issue 4, Supplement, October 2014, Pages A40